. 2022 Feb 13;13(2):839–857. doi: 10.1002/jcsm.12928

Table 1.

Characteristics of included studies listed by HRQOL assessment tool

Author (year)	Country	Study design	Cancer type/s	Sample size	Gender, Female n (%)	Setting	Age, years, mean ± SD	Body composition analysis software	Body composition measure (s)	Site of CT analysis	HRQOL assessment tool
Gigic et al. (2020) ⁴³	Germany	Prospective cohort	Colorectal	138	39 (28)	Outpatient	61 ± 11.5	Syngo Volume tool	SMI VFA SFA	L3/4	EORTC QLQ‐C30
Derksen et al. (2020) ⁴²	Netherlands	Prospective cohort	Colorectal	221	79 (36)	Outpatient	63.5 ± 8.4	SliceOmatic	SMI	L3	EORTC QLQ‐C30
Daly et al. (2020) ⁴¹	Ireland, Scotland	Cross‐sectional	Gastrointestinal (40%) Lung (26%) Other (34%) ^a	1027	503 (49)	Inpatient and outpatient	Median (IQR) 66 (57–74)	Ireland: OsiriX software version 4.1.1 Scotland: ImageJ software (version 1.47)	SMI MA	L3	EORTC QLQ‐C30
Blauwhoff‐Buskermolen et al. (2017) ⁴⁰	Netherlands	Cross‐sectional	Colorectal Lung Breast Prostate	241	111 (46)	Outpatient	64 ± 10	SliceOmatic	SMI	L3 or T4	EORTC QLQ‐C30
Bye et al. (2017) ²⁷	Norway	Cross‐sectional	Lung	734	314 (43)	Outpatient	65.4 ± 9.4	SliceOmatic	SMI SMD	L3	EORTC QLQ‐C30 EORTC QLQ‐LC13
Huang et al. (2017) ⁴⁵	China	Before–after	Gastric	110	29 (26)	Outpatient	63.2 ± 10.4	INFINITT Healthcare Version 3.0.11.3	SMI	L3	EORTC QLQ‐C30 EORTC QLQ‐STO22
van Roekel et al. (2017) ⁴⁹	Netherlands	Cross‐sectional	Colorectal	104	42 (40)	Outpatient	64.3 ± 9	SliceOmatic	SMI VAT IMAT MA	L3	EORTC QLQ‐C30
Thoresen et al. (2012) ⁴⁸	Norway	Prospective cohort	Colorectal	50	24 (48)	Outpatient	Median (IQR) 64 (41–85)	SliceOmatic	SMI	L3	EORTC QLQ‐C30
Aleixo et al. (2020) ³⁹	USA	Cross‐sectional	Breast	99	99 (100)	Outpatient	56.4 ± 13.1	SliceOmatic	SMI SMD SMG	L3	FACT‐G
Sheean et al. (2019) ⁴⁷	USA	Cross‐sectional	Breast	41	41 (100)	Outpatient	59.6 ± 11.9	SliceOmatic	SMI SMD VAT SAT TAT	L3	FACT‐B FACT‐ES
Nipp et al. (2018) ²⁸	USA	Cross‐sectional	Lung (56.5%) Gastrointestinal (43.5%)	237	109 (46)	Outpatient	64.4 ± 10.9	OsiriX	SMI	L3	FACT‐G
Hua et al. (2020) ⁴⁴	China	Before–after	Nasopharyngeal	56	9 (16)	Outpatient	44.2 ± 10.93	Monarco TPS	SMI	C3 (converted to L3) ^b	WHOQOL‐100
Mitsui et al. (2020) ⁴⁶	Japan	Retrospective cohort	Prostate	301	301 male (100)	Outpatient	Median (IQR) 68 (63–71)	Synapse Vincent V4	SMI VATI SATI	L3	EPIC
Wang et al. (2016) ⁵⁰	USA	Before–after	Oropharyngeal	50	2 (4)	Outpatient	57 ± 7	MATLAB version 13.0	Total psoas area Lean psoas area SMD	L4	UWQOL HNQOL

^{^a}

Breast, gynaecologic, genitourinary, neurologic, haematological, melanoma, unknown primary, and others.

^{^b}

Skeletal muscle area at L3 estimated using published formula. ⁵¹

EORTC QLQ‐C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire – Core 30 ²⁰ ; EORTC QLQ‐STO22, Gastric cancer module ⁵² ; EPIC, Expanded Prostate Cancer Index Composite instrument ⁵³ ; FACT‐G, Functional Assessment of Cancer Therapy – General ⁵⁴ ; FACT‐B, Breast ⁵⁵ ; FACT‐ES, Endocrine Symptoms ⁵⁶ ; HNQOL, Head and Neck Quality of Life Instrument ⁵⁷ ; HRQOL, health‐related quality of life; HU, Hounsfield Units; IMAT, intermuscular adipose tissue; IQR, interquartile range; MA, mean muscle attenuation [mean radiodensity (in HU) of cross‐sectional muscle area]; PD1, first progression of disease; SAT, subcutaneous adipose tissue (interchangeable with SFA); SATI, subcutaneous adipose tissue index; SD, standard deviation; SFA, subcutaneous fat area (interchangeable with SAT); SMD, skeletal muscle radiodensity (a measurement of MA); SMG, skeletal muscle gauge (SMI × SMD); SMI, skeletal muscle index; SMM, skeletal muscle mass; TAT, total adipose tissue (SAT + VAT); TPA, total psoas area; UWQOL, University of Washington Quality of Life Instrument ⁵⁸ ; VAT, visceral adipose tissue (interchangeable with VFA); VATI, visceral adipose tissue index; VFA, visceral fat area (interchangeable with VAT); WHOQOL‐100, The World Health Organization Quality of Life assessment. ⁵⁹